Agilent Technologies Inc (A)vsCharles River Laboratories (CRL)
A
Agilent Technologies Inc
$126.49
-2.12%
HEALTHCARE · Cap: $36.67B
CRL
Charles River Laboratories
$181.34
-2.40%
HEALTHCARE · Cap: $9.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 80% more annual revenue ($7.23B vs $4.03B). A leads profitability with a 19.6% profit margin vs -4.6%. CRL appears more attractively valued with a PEG of 0.12. A earns a higher WallStSmart Score of 71/100 (B).
A
Strong Buy71
out of 100
Grade: B
CRL
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$74.53
Current Price
$126.49
$51.96 premium
Margin of Safety
-2.5%
Fair Value
$161.89
Current Price
$181.34
$19.45 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 60.0% YoY
Strong operational efficiency at 23.7%
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Weak financial health signals
1.2% revenue growth
Elevated debt levels
ROE of -6.3% — below average capital efficiency
Earnings declined 17.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CRL
The strongest argument for CRL centers on PEG Ratio, Price/Book. PEG of 0.12 suggests the stock is reasonably priced for its growth.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : CRL
The primary concerns for CRL are Revenue Growth, Debt/Equity, Return on Equity.
Key Dynamics to Monitor
A profiles as a mature stock while CRL is a turnaround play — different risk/reward profiles.
CRL carries more volatility with a beta of 1.45 — expect wider price swings.
A is growing revenue faster at 10.0% — sustainability is the question.
A generates stronger free cash flow (184M), providing more financial flexibility.
Bottom Line
A scores higher overall (71/100 vs 43/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Charles River Laboratories
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?